Obalon Therapeutics (OBLN): Q3 EPS of -$0.61 may not be comparable to consensus of -$5.70. Revenue of $0.33M (-89.0% Y/Y) misses by $1.17M. Shares +4.47% P
Obalon Therapeutics ([[OBLN]] -1.1%) promotes President and CFO William Plovanic to President & CEO, succeeding Kelly Huang who departed after less than fi
Investing.com – U.S. stocks were mixed after the close on Wednesday, as gains in the Telecoms, Technology and Financials sectors led shares higher while losses in the Consumer...
Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Dow Jones fell 6.7%, the S&P 500 shed 6.6% and the Nasdaq tumbled 7.9%. Rough...
It has been a choppy ride for the stock market so far this year. The U.S.-China trade war, uncertainty over Brexit, tech weakness, declining oil prices, the U.S. Federal...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Neutral||Sell||Strong Sell||Strong Sell|
|Technical Indicators||BUY||BUY||BUY||Strong Sell||Strong Sell|
|Summary||Buy||Neutral||Neutral||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish doji Star||1W||Current|
|Bullish doji Star||1M||Current|
|Homing Pigeon||30||3||Nov 13, 2019 10:30AM|
|Deliberation Bearish||15||3||Nov 13, 2019 11:15AM|
|Doji Star Bearish||15||3||Nov 13, 2019 11:15AM|
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.